Survival of MM patients with compared with those without high-risk genetic features
| Genetics . | Np/Na . | End point . | Therapy . | Present . | Absent . | Comment . |
|---|---|---|---|---|---|---|
| Conventional therapy | ||||||
| t(4;14) | 42/290 | 3-y OS | VBMCP | 24% | 64% | E948613 |
| 100/616 | 3-y OS | VAD + ASCT × 2 | 55% | 80% | IFM-996 | |
| 98/414 | 3-y OS | VAD + ASCT × 1/2 | 40% | 72% | IFM-200539 | |
| del17p | 37/308 | 3-y OS | VBMCP | 32% | 68% | E948613 |
| 58/474 | 3-y OS | VAD + ASCT × 2 | 50% | 78% | IFM-996 | |
| 119/393 | 3-y OS | VAD + ASCT × 1 | 49% | 82% | IFM-200539 | |
| Unfavorable FISH | 141/166 | 3-y OS | CVAD + ASCT × 1 | 58% | 81% | MRC IX intensive51 |
| 90/125 | 3-y OS | MP | 26% | 48% | MRC IX nonintensive9 | |
| 98/129 | 3-y OS | Placebo maintenance | 69% | 72% | MRC IX maintenance54 | |
| 18/111 | 3-y OS | VBMCP/VBAD + Bz × 2 + ASCT × 1 | 48% | 84% | GEM2005 < 6550 | |
| Thalidomide | ||||||
| t(4;14) | 57/181 | 3-y PFS | TD + ASCT × 2 + TD | 20% | 48% | GIMEMA43 |
| 26/156 | 3-y OS | VAD + ASCT × 1 + Thal maintenance | 44% | 79% | HOVON/GMMG7 | |
| del17p | 21/161 | 3-y OS | VAD + ASCT × 1 + Thal maintenance | 17% | 79% | HOVON/GMMG7 |
| Unfavorable FISH | 43/302 | 5-y OS | Thal induction, consolid, maintenance | 56% | 72% | Total Therapy 241 |
| 152/167 | 3-y OS | CTD + ASCT × 1 | 59% | 82% | MRC IX intensive51 | |
| 96/129 | 3-y OS | CTDa | 58% | 78% | MRC IX nonintensive9 | |
| 99/126 | 3-y OS | Thalidomide maintenance | 45% | 76% | MRC-IX maintenance54 | |
| 17/110 | 3-y OS | TD + ASCT × 1 | 56% | 86% | GEM2005 < 6550 | |
| Lenalidomide | ||||||
| t(4;14) | 28/102 | Median OS | LD in RRMM | 18 m | 23 m | MM-01645 |
| 26/158 | Median OS | LD in RRMM | 9 m | 15 m | IFM46 | |
| 152/355 | Median PFS | Lenalidomide maintenance | 27 m | 42 m | IFM-200547 | |
| del17p | 12/118 | Median OS | LD in RRMM | 4 m | 23 m | MM-01645 |
| 6.6% | Median PFS | Lenalidomide maintenance | 29 m | 42 m | IFM 200547 | |
| Unfavorable FISH | 16/84 | 3-y OS | LD | 77% | 86% | Mayo55 |
| 21/105 | 2-y OS | LD | 76% | 91% | E4A0356 | |
| Bortezomib | ||||||
| t(4;14) | 106/401 | 4-y OS | BzD + ASCT × 1 | 63% | 85% | IFM-200539 |
| 53/183 | 3-y PFS | BzTD + ASCT × 2 + BzTD | 65% | 61% | GIMEMA43 | |
| 24/148 | 3-y OS | BzAD + ASCT × 1 + Bz | 66% | 82% | HOVON/GMMG7 | |
| del17p | 54/453 | 4-y OS | BzD + ASCT × 1 | 50% | 79% | IFM-200539 |
| 16/156 | 3-y OS | BzAD + ASCT × 1 + Bz | 69% | 82% | HOVON/GMMG7 | |
| Unfavorable FISH | 18/112 | 3-y OS | BzTD + ASCT × 1 | 60% | 88% | GEM2005 < 6550 |
| 44/188 | 3-y OS | BzMP/BzTP then BzT/BzP | 55% | 73% | GEM2005 > 6558 | |
| 28/140 | 3-y OS | BzMP | 56% | 71% | VISTA57 |
| Genetics . | Np/Na . | End point . | Therapy . | Present . | Absent . | Comment . |
|---|---|---|---|---|---|---|
| Conventional therapy | ||||||
| t(4;14) | 42/290 | 3-y OS | VBMCP | 24% | 64% | E948613 |
| 100/616 | 3-y OS | VAD + ASCT × 2 | 55% | 80% | IFM-996 | |
| 98/414 | 3-y OS | VAD + ASCT × 1/2 | 40% | 72% | IFM-200539 | |
| del17p | 37/308 | 3-y OS | VBMCP | 32% | 68% | E948613 |
| 58/474 | 3-y OS | VAD + ASCT × 2 | 50% | 78% | IFM-996 | |
| 119/393 | 3-y OS | VAD + ASCT × 1 | 49% | 82% | IFM-200539 | |
| Unfavorable FISH | 141/166 | 3-y OS | CVAD + ASCT × 1 | 58% | 81% | MRC IX intensive51 |
| 90/125 | 3-y OS | MP | 26% | 48% | MRC IX nonintensive9 | |
| 98/129 | 3-y OS | Placebo maintenance | 69% | 72% | MRC IX maintenance54 | |
| 18/111 | 3-y OS | VBMCP/VBAD + Bz × 2 + ASCT × 1 | 48% | 84% | GEM2005 < 6550 | |
| Thalidomide | ||||||
| t(4;14) | 57/181 | 3-y PFS | TD + ASCT × 2 + TD | 20% | 48% | GIMEMA43 |
| 26/156 | 3-y OS | VAD + ASCT × 1 + Thal maintenance | 44% | 79% | HOVON/GMMG7 | |
| del17p | 21/161 | 3-y OS | VAD + ASCT × 1 + Thal maintenance | 17% | 79% | HOVON/GMMG7 |
| Unfavorable FISH | 43/302 | 5-y OS | Thal induction, consolid, maintenance | 56% | 72% | Total Therapy 241 |
| 152/167 | 3-y OS | CTD + ASCT × 1 | 59% | 82% | MRC IX intensive51 | |
| 96/129 | 3-y OS | CTDa | 58% | 78% | MRC IX nonintensive9 | |
| 99/126 | 3-y OS | Thalidomide maintenance | 45% | 76% | MRC-IX maintenance54 | |
| 17/110 | 3-y OS | TD + ASCT × 1 | 56% | 86% | GEM2005 < 6550 | |
| Lenalidomide | ||||||
| t(4;14) | 28/102 | Median OS | LD in RRMM | 18 m | 23 m | MM-01645 |
| 26/158 | Median OS | LD in RRMM | 9 m | 15 m | IFM46 | |
| 152/355 | Median PFS | Lenalidomide maintenance | 27 m | 42 m | IFM-200547 | |
| del17p | 12/118 | Median OS | LD in RRMM | 4 m | 23 m | MM-01645 |
| 6.6% | Median PFS | Lenalidomide maintenance | 29 m | 42 m | IFM 200547 | |
| Unfavorable FISH | 16/84 | 3-y OS | LD | 77% | 86% | Mayo55 |
| 21/105 | 2-y OS | LD | 76% | 91% | E4A0356 | |
| Bortezomib | ||||||
| t(4;14) | 106/401 | 4-y OS | BzD + ASCT × 1 | 63% | 85% | IFM-200539 |
| 53/183 | 3-y PFS | BzTD + ASCT × 2 + BzTD | 65% | 61% | GIMEMA43 | |
| 24/148 | 3-y OS | BzAD + ASCT × 1 + Bz | 66% | 82% | HOVON/GMMG7 | |
| del17p | 54/453 | 4-y OS | BzD + ASCT × 1 | 50% | 79% | IFM-200539 |
| 16/156 | 3-y OS | BzAD + ASCT × 1 + Bz | 69% | 82% | HOVON/GMMG7 | |
| Unfavorable FISH | 18/112 | 3-y OS | BzTD + ASCT × 1 | 60% | 88% | GEM2005 < 6550 |
| 44/188 | 3-y OS | BzMP/BzTP then BzT/BzP | 55% | 73% | GEM2005 > 6558 | |
| 28/140 | 3-y OS | BzMP | 56% | 71% | VISTA57 |
V indicates vincristine; A, adriamycin; D, dexamethasone; ASCT, autologous stem cell transplantation; Thal, thalidomide; Bz, bortezomib; M, melphalan; P, prednisone; B, BCNU; C, cyclophosphamide; L, lenalidomide; RRMM, relapsed refractory multiple myeloma; and /, sequental therapies.